<DOC>
	<DOCNO>NCT01420913</DOCNO>
	<brief_summary>The purpose trial compare pharmacokinetic characteristic YHD1119 A , YHD1119 B , YHD1119 C Lyrica capsule . YHD1119 A , B , C control release formulation make YUHAN Corporation . Primary endpoint C max , ss AUC tau . Secondary endpoint AUC last , AUC infinity , T max , s , 1/2</brief_summary>
	<brief_title>Randomized , Open-label , Parallel Study Evaluate Pharmacokinetic Characteristics Pregabalin According Different Controlled Released Formulations Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pregabalin</mesh_term>
	<criteria>20~45 year old , healthy adult male subject &gt; 55 Kg ( Body weight ) &lt; ideal body weight Â± 20 % AST ALT &gt; 1.25 * Upper normal range ( Lab ) Total bilirubin &gt; 1.5 * Upper normal range Systolic BP &gt; 140 OR &lt; 100 , Diastolic BP &gt; 90 OR &lt; 65</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>To evaluate pharmacokinetic characteristic Lyrica , YHD1119 A , B , C</keyword>
</DOC>